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Abstract 
 
Adynamic Bone disease is a bone and mineral disorder that reflects abnormalities in 
calcium homeostasis with low calcium buffer capacity and inability to handle this ion’s 
extra load. Its prevalence has been rising in the latest two decades as a result of 
generalized use of calcium-containing phosphate binders combined with vitamin D 
receptor agonists. The association between Adynamic Bone Disease and diabetes 
mellitus, as well as peritoneal dialysis, the Wnt signaling inhibitor sclerostin and the 
malnutrition-inflammation complex reflects the unknown multifactorial causes that lead 
to this disease. The gold-standard method for the diagnosis of Adynamic Bone Disease 
is bone biopsy with tetracycline labeling, however, this is an invasive, expensive method 
that is not widely available, and so, biochemical markers, such as serum Parathyroid 
Hormone are used to make the diagnosis, even though they cannot fully replace bone 
biopsy. One of the greatest burdens of Chronic Kidney Disease is vascular calcification. 
This active process leads to arterial stiffening and to higher cardiovascular and non-
cardiovascular mortality rates. Interestingly, lower levels of Parathyroid Hormone, as 
seen in patients with Adynamic Bone Disease, are associated with higher mortality rates 
than higher levels. The objectives of the treatment of this disorder are mainly to prevent 
the excessive calcium load, using lower calcium dialysate, non-calcium-containing 
phosphate binders and avoiding Vitamin D therapy. Some novel therapies are being 
tested, such as Teriparatide and Menatetrenone, but no definite conclusions can be 
taken at this moment on the effect of these agents.  
 
 
State-of-the-Art-Review 
 
An overview on adynamic bone disease 
 
 
 
4 
 
Introduction 
 
Chronic Kidney Disease (CKD) is an global public health problem affecting 5-10% of the 
world population 1. As the kidney function declines there is a deterioration of the mineral 
homeostasis with altered serum and tissue concentration of phosphorus and calcium as 
well as changes in circulating levels of hormones. In the course of CKD there is a 
reduction in the ability of the kidney to excrete an adequate load of phosphate which 
leads to hyperphosphatemia, elevation of parathyroid hormone (PTH) and FGF-23. The 
conversion of 25(OH)D to 1,25(OH)D is impaired, stimulating PTH secretion. The kidney 
also fails to respond adequately to PTH (that increases calcium reabsorption and 
promotes phosphaturia) and to FGF-23 (that increases phosphaturia). As this functions 
are of crucial importance to the metabolism of bone is not surprising that bone anomalies 
are present in virtually every patient with CKD stage 5D (requiring dialysis) and in the 
majority of patients in stage 3-5 1. Recently, more importance as been given to the 
canonical wnt signaling. Wnt ligands bind to the LRP5/6 membrane receptor complex 
increasing bone formation. Sclerostin is a wnt signaling inhibitor, decreasing bone 
formation and osteoblast activity 2. A cross-sectional study, showed higher levels of 
serum sclerostin in patients with stage 5 CKD when compared to no CKD controls. This 
might be due to an increased retention or production 3.  In this study only sclerostin was 
associated with bone turn-over, pointing to a superior value of this parameter as a non-
invasive indicator of bone turn-over. However, this superiority was only observed in high 
turn-over bone disease. A recent cross-sectional study evaluated serum and trabecular 
bone surface sclerostin in peritoneal dialysis patients showing that, not only were both 
parameters elevated in these patients, but they were also negatively associated to bone 
alkaline phosphatase and bone formation rate 2. When serum and trabecular bone 
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surface sclerostin were analyzed separately in diabetic and nondiabetic patients the 
same study showed that both serum and trabecular bone surface sclerostin were higher 
in the first group. Moreover, there was also showed a difference in the pattern of 
distribution of the trabecular bone surface sclerostin between patients with high turn-over 
(95% of patients with sclerostin expression in deeper osteocytes and only 5% of them 
with diffuse distribution) and low turn-over (52.4% of the patients with sclerostin 
expression in deeper osteocytes and the remaining patients with diffuse distribution). 
This mineral and hormonal changes go beyond bone alterations and are responsible for 
systemic consequences such as vascular calcification 1. These changes have a major 
impact on morbidity and mortality 4 and consequently their control is of great importance 
in CKD patients. Chronic Kidney Disease-Mineral and Bone Disorder (CKD-BMD) should 
be used to refer to this broader clinical syndrome that includes mineral, bone and 
vascular alterations that emerge as a consequence of CKD. Renal osteodystrophy is the 
term used to describe only the bone pathology associated with CKD, which include 
changes in bone turn-over, mineralization and volume 1. The diagnosis of renal 
osteodystrophy requires a bone biopsy and uses a classification based on parameters 
of bone Turn-over, Mineralization and Volume (TMV) 5. Bone turn-over can be classified 
as high, normal or low while mineralization is classified as normal or abnormal. Based 
on this 3 parameters renal osteodystrophy is divides in 6 diseases: hyperparathyroid 
bone disease (high turn-over, normal mineralization and any bone volume), mixed bone 
disease (high turn-over, abnormal mineralization and normal volume), osteomalacia (low 
turn-over, abnormal mineralization and low to normal bone volume), adynamic bone 
disease (ABD) (low turn-over, normal mineralization and normal to low bone volume), 
amyloid bone disease and aluminum bone disease. 
The purpose of this review is to focus primarily on ABD, its etiology, clinical 
manifestations and therapeutical options. 
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Methods 
 
With the purpose of reviewing the current knowledge of ABD in its etiology, clinical 
manifestations and therapeutical options available was conducted a search in the 
Pubmed electronic database including the following key words: chronic kidney disease, 
mineral bone disorder, renal osteodystrophy, adynamic bone disease, low PTH, low turn-
over, vascular calcification, Teriparatide, Sevelamer and Lanthanum carbonate. The 
search was limited to papers published between January 2008 and January 2015 and 
articles in English or Portuguese. Opinion papers and editorials were excluded. Papers 
that, after careful reading of the title, abstract and/or full text, did not met the purpose of 
this review were also excluded. Adding to this, there were also included in the search 
publications referenced in the papers analyzed that brought value to the present review. 
In the end of the process, 57 papers were included. 
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Results 
 
Adynamic bone disease 
ABD is a bone lesion characterized by low bone turn-over, with the dynamic 
histomorphometric parameters both bone formation rate and activation frequency 
markedly reduced, with normal mineralization, which is represented in the bone biopsy 
as an absence of excess osteoid deposition. This happens because in these patients the 
rate of deposition of the osteoid is so low that the mineralization defect is not even 
manifested 6. This absence of osteoid is the major difference between ABD and 
osteomalacia, another low turn-over bone lesion in which the mineralization defect is 
greater than the collagen deposition defect leading to osteoid deposition 6. A reduced 
number of osteoblasts with minimal to none peritrabecular or marrow fibrosis are also 
indicative of ABD 7.  
At the moment, ABD is an important health problem in patients in CKD stage 5. A 
Portuguese study involving hemodialysis population showed that this bone lesion was 
the most common in this population, with a biopsy-proven prevalence of 59% at baseline 
8. This shows the ever growing need to fully understand this disease as well as to develop 
therapeutical approaches that successfully reduce this high prevalence.  
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Etiology of adynamic bone disease 
ABD was first described in association with aluminum overload and this was, in the past, 
the major cause of this bone lesion 9. Aluminum deposition along the calcification fronts 
prevents the mineralization process and also inhibits the deposition of osteoid by directly 
damaging the osteoblasts 10. A chronic low dose exposure to aluminum in association 
with high dosages of vitamin D receptor (VDR) analogs is believe to lead preferentially 
to ABD rather than to osteomalacia 11, the bone lesion most commonly associated with 
aluminum overload. The major sources of aluminum were the dialysate, prior to the use 
of reverse osmosis as a dialysis water treatment, as well as the use of aluminum 
hydroxide as a phosphate binder 7. Although effective, this phosphate binders are no 
longer widely used due to their established toxicity 12. This, in addition to the widespread 
of the reverse osmosis may have been responsible for the decreased aluminum 
intoxication from 40%, in biopsies carried out before 1995 to 20%, in biopsies taken after 
1995 1. Due to this, aluminum induced low turn-over disease as become progressively 
less frequent and, at this moment, is considered a residual lesion 7. 
The incidence of ABD rose again in 1995, this time not associated with aluminum toxicity, 
but as the result of the generalized usage of calcium-containing phosphate binders 13. 
These agents increase calcium load, which leads to the suppression of PTH. Evidence 
that dates back to 1994 shows that ABD isn’t merely an academic finding, but a mineral 
and bone disorder that produces an abnormal calcium homeostasis 14. This study 
showed a normal or slightly decreased plasma calcium efflux and calcium accretion rate 
as well as a disproportionately low calcium retention in patients with low turn-over 
disease. This results in a very low capacity to buffer calcium and also an inability to 
handle extra calcium load. Also, the suppression of PTH is especially striking when 
calcium-containing phosphate binders are combined with VDR agonists, which further 
suppress PTH secretion. This knowledge has led to changes in the treatment of patients 
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with ABD, including the discontinuing of the intravenous vitamin D therapy, as well as 
the substitution of calcium-containing phosphate binders with the newer non- calcium-
containing phosphate binders, such as sevelamer and lanthanum carbonate 15. The 
purpose of these changes is to avoid further reduction of PTH secretion, which increases 
the risk of ABD. However, the emergence of selective VDR agonists, such as paricalcitol, 
may cause changes in the way we treat ABD. This new agents showed a lower risk of 
hypercalcaemia, hyperphosphatemia and elevated calcium-phosphate products levels 
when compared to the active vitamin D formulations, such as calcitriol 16. This data 
combined with some recent studies that suggest that patients with PTH <= 150 pg/ml 
receiving VDR agonists, specially paricalcitol, have lower mortality rates than untreated 
patients 17 may indicate a role for selective VDR agonists in the treatment of ABD, 
however, more studies need to be conducted in order to fully understand this association.  
ABD is also associated with clinical factors, such as older age, peritoneal dialysis and 
diabetes mellitus 13. The association with peritoneal dialysis was studied in a recent 
cross-sectional study in which bone histomorphometry revealed lower turn-over 
parameters and worst mineralization in peritoneal dialysis patients when compared to 
hemodialysis patients 2. The same study also showed a much larger prevalence of ABD 
in diabetic patients (78%) when compared to nondiabetic patients (26%). Three 
hypotheses have been proposed to explain the great influence of diabetes mellitus on 
the development of ABD. The first one states that advanced glycation products stimulate 
osteoblast apoptosis and therefore, reduce bone formation 18. The second hypothesis 
claims that low vitamin D in diabetic patients is implicated in the pathogenesis of this 
disease15. The third and most recent one asserts that the reduced bone turn-over found 
in diabetic patients is mediated by sclerostin, the wnt signaling inhibitor, which is elevated 
in this group of patients 2. Malluche et al, in 2011, showed that white patients are more 
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likely to present with low turn-over than black patients 19. This association had not been 
reported in previous studies.  
Recently, the hypothesis that low PTH, the primary biochemical marker for ABD, might 
be associated with the malnutrition-inflammation complex has been explored. A study by 
Dukkipati et al showed that low PTH was associated with energy-wasting and 
inflammation and that this association virtually nullified any possible relation between 
PTH and alkaline phosphatase in these PTH ranges 20. This study also showed that, 
when corrected for case-mix and surrogates of malnutrition and inflammation, a PTH in 
the range of 100-150 pg/ml was associated with greater survival when compared to other 
ranges of PTH. This is of clinical importance as it might signify that after controlling the 
malnutrition-inflammation complex, a level of PTH under the KDIGO guidelines 
recommended range of 150-300 pg/ml is associated with a greatest survival. Other 
authors have postulated that ABD might be a secondary phenomenon and a 
consequence of the malnutrition-inflammation complex 21  and these results might point 
to this direction. 
These findings point to a multifactorial etiology of ABD, with more contributing elements 
than those known at this point. In order to properly diagnose and manage patients that 
already have ABD, as well as to prevent the development of this disease in CKD stage 
5 patients,  is important to conduct more studies that help us understand not only which 
are these unknown factors, but also has they connect with each other.  
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Diagnosis of adynamic bone disease 
The definitive diagnosis of renal osteodystrophy, requires a bone biopsy 1. This is done 
by the histomorphometric analysis of an undecalcified bone sample that requires a pre-
biopsy tetracycline labelling as well as aluminum and amyloid stains for a complete work-
up. In order to correctly diagnosis and differentiate the different types of renal 
osteodystrophy assessment of bone turn-over, mineralization and fibrosis are required 
11.  However, in clinical practice, this can’t always be done because it is an invasive, time 
consuming, and expensive procedure not widely available 5. Considering this, 
biochemical abnormalities are the most commonly used  indicators by which the 
diagnosis of MBD is made 1 even with the knowledge that none of the biochemical 
markers for bone reabsorption, formation or parathyroid status are accurate enough to 
replace the  bone biopsy 11. 
According to the Kidney Disease Outcomes Quality Initiative, in patients with CKD stage 
5, PTH concentration should be measured regularly and maintained within 150-300 
pg/ml. However, Barreto et al showed that even within the target range (150-300 pg/ml) 
the most common finding on bone biopsy was low turn-over (n=22, 63,6%) and that only 
a small number of patients in this range presented with normal bone turn-over (n=22, 
9%) 22. A study with overlapping results was performed in Portugal by Ferreira et al in 
which a prevalence of ABD of 59% with PTH levels within KIDIGO target range is 
reported 8.  
The first generation of PTH assays were radioimmunoassays which measured not only 
the PTH 1-84 molecule but also its fragments produced in the liver and eliminated by the 
kidney that accumulate in patients with CKD, producing highly increased levels of PTH 
and with poor sensitivity for low PTH concentration 23. These assays are considered 
obsolete in the present day. Serum PTH is a combination of PTH1-84, the full hormone, 
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as well as its carboxy-terminal fragments 24. The most important of this fragments is 
PTH7-84, which is also detected by the second generation PTH assays, the intact PTH 
assays 25. More recently, the third generation assays, the whole PTH assays, where 
developed. Using an N-terminal antibody directed against the first amino-acids this assay 
does not measure the PTH 7-84 23. Therefore, the difference between the values 
measured with the intact PTH assay and the whole PTH assay represents the PTH 7-84 
concentration. 
It has been demonstrated that PTH 7-84 antagonizes the calcemic response to PTH 1-
84, probably modulating the effects of PTH 1-84 on bone 25. This antagonizing effect was 
explored Mauniere-Faugere et al in a study that proposes the use of the PTH 1-84/PTH 
Carboxy terminal fragments ratio as a method of predicting bone turn-over 26. The study 
showed the superiority of this ration in predicting bone turn-over when compared to all 
other biochemical markers, alone or in combination. Predominance of the active PTH 1-
84 form is associated with high bone turn-over and predominance of the PTH Carboxyl 
terminal fragments is associated with low bone turn-over. However, this superiority was 
not confirmed in a more recent report 27. 
Both the second and third generation assays are used in the clinical practice introducing 
a great inter-method variability. The intra-method variability also represents a problem 
and its due to the lack of standardization and antibody specificity25.  
Bone alkaline phosphatase is a fraction of the serum alkaline phosphatase produced by 
the osteoblasts. It is very important marker of bone formation and its elevated levels 
virtually exclude the presence of ABD 7. A recent study with 41 peritoneal dialysis 
patients demonstrated that bone alkaline phosphatase was, not only, a good marker for 
bone turn-over, but a slight superiority of bone alkaline phosphatase was found when 
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compared to intact PTH 2. This biochemical parameter is particularly useful in patients 
with liver disease.  
Serum PTH values below 100pg/ml or above 800pg/ml have a good diagnostic value for 
ABD and high turn-over disease, respectively. Is in the patients presenting with serum 
PTH levels between 100pg/ml and 500pg/ml that lays the greater difficulty in reaching a 
satisfying diagnosis without performing a bone biopsy 7.   
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Clinical presentation of adynamic bone disease 
Bone Fractures 
Due to the impaired bone remodeling process, patients with ABD have poorer repair of 
microfractures.  This leads to more frequent episodes of fractures 28. A study by Atsumi 
et al that evaluated compression vertebral fractures in hemodialysis patients showed that 
the subgroup with the lowest percentile of PTH had the highest risk of these fractures 29. 
Another study, by Coco et al, presented similar results with hip fractures, with patients 
with the lower PTH levels being more likely to sustain hip fractures than the ones with 
higher PTH levels 30. In both studies, patients with CKD presented with significantly 
higher fracture risk than the patients without CKD.  
 
Cardiovascular calcification 
Cardiovascular calcifications represent an important problem in patients with End Stage 
Renal Disease 11. Besides common atherosclerosis with patchy calcification of 
atherosclerotic plaques, hemodialysis patients also present mediasclerosis 31. The 
second one seems to be related to mineral disturbances associated with CKD and 
represents an active process in which vascular muscle cells differentiate into osteoblasts 
as a response to stimuli such as hyperphosphatemia 31. To establish the influence of 
hyperphosphatemia and its mechanisms in vascular calcification a human aortic muscle 
cell culture was exposed to phosphate levels comparable to those found in 
hyperphosphatemic patients and a dose-dependent increase in cell culture calcium 
deposition was showed. Also, when exposed to these levels of phosphate, an enhanced 
expression of osteocalcin and Cbfa-1, known osteogenic markers, was shown. These 
changes were mediated by a sodium-dependent phosphate cotransporter (NPC)31. 
These findings reveal the active nature of this process, but, such as this one, there are 
State-of-the-Art-Review 
 
An overview on adynamic bone disease 
 
 
 
15 
 
probably more pathways involved in vascular calcification, and for this reason the 
continuing search on this area is of great importance. 
Cardiovascular calcification represents an important problem due to its impact in 
mortality and morbidity. Coronary artery calcification progression was associated with 
progressive deterioration of arterial stiffness and cardiac repolarization 32.  Another study 
reported that the presence of arterial calcifications in end stage renal disease is highly 
predictive of all-cause mortality and cardiovascular mortality and also that arterial media 
calcifications represent an independent prognostic marker for all-cause mortality as well 
as cardiovascular mortality in hemodialysis patients 33. A simple vascular calcification 
score based on plane radiographic films of the pelvis and hands has shown to be a 
simple tool useful to the assessment of cardiovascular risk related to vascular 
calcification in hemodialysis patients 34. A score of 3 or higher was independently 
associated with peripheral artery disease, coronary artery disease and vascular disease. 
These patients also presented a 3.9 fold increase risk of cardiovascular mortality, a 2.9 
fold increase in cardiovascular hospitalizations as well as a 2.4 fold increase in the risk 
of fatal and nonfatal cardiovascular events.  
The association between cardiovascular calcification and low bone turn-over has been 
described by several authors. A study, published in 2004 by London et al, compared 
bone histomorphometric characteristics with the arterial calcification scores (0 to 4) which 
were determined through the number of sites with arterial calcifications using ultrasound 
evaluation. The study showed that patients with highest arterial calcifications scores (3 
and 4) had lower PTH levels, lower osteoclast numbers and osteoblastic surfaces, 
smaller or absent double tetracycline-labeled surfaces as well as higher percentages of 
aluminum stain surfaces, which reveals an association between high arterial calcification 
and low bone activity and ABD. The data analysis concluded that arterial calcification 
had an inverse correlation with osteoblastic surfaces. Later, in 2008, the same author 
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conducted a study to evaluate the interaction between bone activity, assessed by 
histomorphometric analysis, and the use of calcium-containing phosphate binders with 
the extent of abdominal aortic calcification and aortic stiffness, assessed by pulse wave 
velocity, in hemodialysis patients 35. In this study, not only biopsy proven ABD was 
associated with greater aortic stiffness independently of any other factor, but also, 
patients with ABD showed stronger association between calcium load and aortic 
calcification score and aortic stiffness. This indicates that the presence of ABD disease 
conferred a greater influence of calcium load to both aortic calcification and stiffening.  
A cohort study nested within a randomized controlled trial was performed to evaluate the 
association between bone remodeling disorders and progression of vascular 
calcification, more specifically, coronary artery calcification 36. Biochemcial parameters 
of bone activity were evaluated throughout the study and bone histomorphometry was 
assessed at baseline and after 1 year of follow-up. Coronary artery calcification was 
assessed by coronary multislice tomography at baseline and after 1 year of follow-up, 
with a score of 30 Agatston units of greater at baseline representing calcification and a 
change in the score of 15% or greater representing progression. Patients with a biopsy 
proven low turn-over disease at baseline who showed higher bone formation rate and 
osteoid volume at follow-up were associated with lower coronary artery calcification 
progression. Also, patients with lesser coronary artery calcification progression 
presented greater levels of bone specific alkaline phosphatase at follow-up. Low bone 
turn-over status was the only independent predictor of coronary artery calcification 
progression at the 12-month bone biopsy. 
A more recent study, involving 207 CKD stage 5 patients, evaluated the association 
between bone turn-over, assessed by histomorphometric analysis, and coronary artery 
calcification, measured using multi-slice computed tomography 37. A negative 
association between activation frequency and coronary artery calcification score and 
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bone formation rate/bone surface and coronary artery calcification scores was found in 
patients with low turn-over.   
The recent recognition of the Wnt signal inhibitor sclerostin as an important regulator of 
bone metabolism has led to its study as a mediator in vascular calcification and it has 
already been shown that sclerostin is expressed in calcifying vasculature 38. A 2013 post-
hoc survival analysis showed that hemodialysis patients with levels of sclerostin above 
median, after adjustment for age and gender, had a significant greater survival 39. The 
authors explain this finding through the pre-existing hypothesis that the expression of 
wnt signaling inhibitors in calcifying vascular tissue may be a defensive response to limit 
the ossification and therefore limit the progression of the vascular calcification. 
Interestingly, a 2014 study with a cohort of 91 patients followed during a ten-year period 
showed that high sclerostin was associated with cardiovascular mortality, independently 
from diabetes and age 40. Some reasons for this discrepancy were postulated by the 
authors, including the younger cohort and lesser percentage of diabetic patients, as well 
as the adjustment for diabetes in the more recent study. These inconsistencies in the 
results reveal a need for further investigation on this matter, ideally with large scale 
studies. 
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Therapeutic approaches to adynamic bone disease 
Low calcium dialysate and calcium profiling 
Numerous investigators have suggested the use of low calcium dialysate in hemodialysis 
patients as a way to lower the risk of hypercalcaemia and excessive PTH suppression. 
A 6 months study with 60 patients with pre dialysis intact PTH<100 pg/ml equally 
distributed over low dialysate calcium (1.25mmol/l) and high dialysate calcium 
(1.75mmol/l) explored this hypothesis 41. The mean of total and ionized calcium was 
markedly increased in the high calcium dialysate at the end of dialysis. This was not 
observed in the low calcium dialysate group, where there were no differences in these 
parameters at baseline and end of dialysis. As expected, total and ionized calcium were 
significantly higher in the high calcium dialysate group when compared to the low calcium 
dialysate group throughout the study. Intact PTH, total alkaline phosphatase and bone 
alkaline phosphatase increased from baseline in the low calcium dialysate group. 
Moreover, all parameters reached higher levels in the low calcium dialysate when 
compared with the high calcium dialysate. These results suggest a benefic effect of low 
calcium dialysate on improving adynamic bone. 
A prospective trial involved 425 hemodialysis patients who with a follow up of 24 months 
explored the effects of lowering the calcium dialysate in bone histomorphometry and in 
the progression of the coronary artery calcification score 42. All patients had a 
PTH<300pg/ml and prior treatment with 1.5ml/L calcium dialysate. Patients receiving 
treatment with vitamin D in the preceding six months were excluded. Patients were 
randomized in to either 1.25ml/L or 1.75ml/L dialysate calcium. Bone biopsy was 
performed at baseline and after 24 months of follow-up. Bone histomorphometric 
analysis showed that bone formation rate, osteoblast surface/bone surface ratio as well 
as bone volume/tissue volume ratio increased in the group with the lowest calcium 
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dialysate, but not in the one with the highest. PTH levels were also significantly higher in 
the low calcium dialysate patients. These findings showed an improvement in bone 
formation and in bone turnover with the use of low calcium dialysate hemodialysis 
leading to an improvement of adynamic bone disease. Moreover, coronary artery 
calcification progression was significantly less pronounced in the group with the low 
calcium dialysate. Similar results regarding bone formation rate and PTH had already 
been reported in 2006 28, however the great strength of this more recent study is the 
large number of patients enrolled and evaluated.  
Low calcium dialysate is, however, associated with some harmful effects such as 
hemodynamic instability and cardiac rhythm disturbances. Calcium profiling with a 
profiled dialysate calcium concentration from 1.63mM/l at the beginning of the session 
to 1.93mM/l at the end was assessed in a multicenter, prospective, randomized trial 43. 
Patients in the calcium profiling group were compared with patients treated with low 
calcium dialysate (1.25mM/l) and with high calcium dialysate (2mM/l). Total amount of 
calcium given to the patient in the profiling group was higher than in the low calcium 
dialysate group, but lower than in the high calcium dialysate group. This higher amount 
of calcium was contra balanced by the absence of the systolic and diastolic arterial 
pressure decrease seen in the low calcium dialysate group. This results show that 
calcium profiling in hemofiltration is a way to guarantee cardiovascular stability during 
the hemodialysis session while reducing the risk of calcium overload. More studies need 
to be done to assess the effects of calcium profiling in bone parameters and, if possible, 
in bone histomorphometry.  
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Non-calcium phosphate binders 
Although used widely to maintain the serum phosphate within the target values, calcium-
containing phosphate binders are associated with a positive calcium balance, 
hypercalcaemia, parathyroid gland suppression, ABD and coronary and aortic 
calcification 44. With the advent of the non-calcium phosphate binders their effect on 
mortality, bone histology, vascular calcification, safety and effectiveness has been 
evaluated.  
Sevelamer hydrochloride 
Sevelamer hydrochloride is an aluminum and calcium free, non-absorbed polymer, with 
no potential for systemic accumulation. In a multicenter, prospective, randomized, no-
blinded study, 212 patients were randomized to either sevelamer hydrochloride or 
calcium carbonate 45. Sevelamer treated patients presented with significantly lower final 
and on-treatment phosphorus levels, although the proportion of patients on CKD stage-
specific target of serum phosphorus was identical between the two groups. Sevelamer 
treated patients also presented a better PTH control and a final and on-treatment 
decreased serum calcium concentration. Adding to this, final and on-treatment average 
total cholesterol and LDL-cholesterol were significantly reduced in the sevelamer group. 
In this study the rate of all cause mortality, dialysis inception and the composite endpoint 
(all cause mortality and dialysis inception) was also significantly less frequent in the 
sevelamer treated patients. Other studies have also showed a decrease in mortality with 
sevelamer compared with calcium carbonate, although without statistical significance 46. 
A randomized clinical trial comparing sevelamer with calcium based phosphate binders 
in 200 hemodialysis patients aimed to compare the calcification of the coronary and 
aortic arteries 47.This study showed that the medium absolute calcium score increased 
significantly in the calcium treated group, but not in the sevelamer group (coronary 
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arteries 36.6 vs. 0 and aorta 75.1 vs. 0, respectively). The medium percent change in 
calcium score was also significantly greater with calcium than with sevelamer in both 
coronary and aortic arteries. Another study in which 129 patients new to hemodialysis 
were randomized to sevelamer or calcium-containing phosphate binders also showed a 
median increase in the coronary artery calcification score significantly greater in the 
calcium treated group. In the other hand, two more recent randomized trials showed no 
significant difference between sevelamer and calcium-containing phosphate binders in 
the coronary artery calcium score 48,49. More independent well designed studies are 
needed in order to definitely clarify this positive impact of sevelamer on vascular 
calcification progression.  
A 54 weeks randomized, open label study performed in 2008 in Portugal involving 119 
hemodialysis patients with biopsies taken at baseline and at the end of the study 8 
showed some changes in the histomorphometric parameters suggestive of increased 
bone turn-over with sevelamer when compared to calcium-containing phosphate 
binders. Although there was no difference between sevelamer or calcium-containing 
binders treated patients regarding change in bone disease classification. An increase in 
bone formation rate was showed in the sevelamer treated group compared to the 
calcium-containing binders patients, but did not reach statistical significance.    
Lanthanum carbonate 
A more recently developed non-calcium phosphate binder, lanthanum carbonate binds 
effectively to phosphate in the stomach, duodenum and jejunum. Lanthanum is primarily 
excreted by the liver and does not appear to cross the blood brain barrier 50. In 2013 a 
systematic review and meta-analysis showed that lanthanum carbonate lowered the 
serum phosphorus level with no difference observed between the lanthanum carbonate 
group and the calcium-containing phosphate binders group or the sevelamer 
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hydrochloride group, with lower levels of serum calcium and higher levels of bone 
specific alkaline phosphatase to those seen with calcium-containing-phosphate-
binders51. This study also showed that lanthanum carbonate has a lower rate intradialytic 
hypotension, cramps or myalgia and abdominal pain than previous phosphate binders. 
It has, however, a higher rate of vomiting when compared to calcium-containing 
phosphate binders. The differences in mortality of lanthanum carbonate versus calcium-
containing phosphate binders were assessed in a 2009 post-hoc survival analysis with 
1354 patients in the course of 24 months 52. At follow up, mortality was higher in the 
calcium treated group (23.3%) than in the lanthanum carbonate treated group, although 
this results did not reach statistical significance. In the subgroup of patients aged >65 
years, however, the results reached statistical significance, with a mortality of 39.3% in 
the calcium treated group and of 27.0% in the lanthanum carbonate treated patients. 
This shows the benefit of the lanthanum carbonate treatment in patients in patients with 
more than 65 years who are likely to carry the greatest burden of vascular calcification. 
Regarding vascular calcification, a pilot randomized control trial was conducted in 45 
hemodialysis patients comparing distributed to either calcium carbonate or lanthanum 
carbonate 53. At 18 months there was significantly less aortic vascular calcification 
progression in the lanthanum carbonate group when compared to the calcium carbonate 
treated patients. There was a similar tendency, although without statistical significance, 
in the progression of vascular calcification in both left and right superficial femoral 
arteries. To assess the effects of lanthanum carbonate on bone a prospective open label 
study in Japanese patients on dialysis was performed with bone biopsies for 
histomorphometric analysis at baseline and after treatment 54. This study showed an 
improvement in osteoid condition toward normalization and also in the reabsorption 
condition toward normalization. After one year of treatment the diagnosis changed to a 
milder type disorder in all patients, including in 2 with ABD at baseline. After 3 years the 
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milder type classification was maintained in all biopsies that were conducted. A major 
limitation in this study in the low number of subjects, with only 14 patients at baseline, 9 
patients completing the one year treatment and only 4 patients completing the 3 year 
treatment. 
 
New approaches  
Teriparatide 
Teriparatide (PTH 1-34) is an osteoanabolic agent in clinical use for the treatment of 
osteoporosis. The use of this agent in the treatment of ABD was hypothesized and 
studied in an open-label, prospective, 6-months, observational pilot study with 7 
hemodialysis patients 55. Bone mineral density of the lumbar spine increased significantly 
after 6 months of therapy. Although there was also a tendency to the increase of bone 
mineral density of the femoral neck, these results were not statistically significant. Serum 
phosphate also showed a significant decrease when compared to pre-treatment values. 
Changes in coronary artery calcification did not reach statistical significance, with 
changes between -17 and +272% compared to baseline studies. The low number of 
participants in this study is a major limitation to this pilot-study. More studies are needed 
in order to fully understand the usefulness of this agent.   
Vitamin K (Menatetrenone) 
Vitamin K has an important role in regulating bone mineralization. The effects of vitamin 
K2 on ABD were evaluated in a study enrolling 40 patients randomly divided in 2 groups, 
one treated with menatetrenone for a year and a control group untreated 56. Bone 
formation markers (intact osteocalcin and bone specific alkaline phosphatase) and bone 
reabsorption marker (NTx) increased in the Vitamin K2 treated patients within a 12 
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months period. This results suggest that vitamin K can improve bone remodeling in 
hemodialysis patients with low PTH. Vitamin K2 treated patients also showed a significant 
increase in PTH levels within 12 months of therapy (baseline: 50.5+-28.0; 12months: 
91.1+-64.8). Serum osteoprotegerin levels, which have been associated with increased 
vascular calcification, showed a decrease after 12 months of treatment. However, no 
histomorphometric analysis was conducted, which is a fundamental step to assess the 
real effect of the therapy in bone remodeling.  
Anti-sclerostin antibody 
In order to determine if anti-sclerostin antibody is efficacious in preventing bone loss in 
animals with high and low PTH, Moe et al induced a slowly progressive model of CKD-
MBD in rats which were then treated with anti-sclerostin antibody 57. The animals were 
sacrificed at 35 weeks. The anti-sclerostin antibody treatment increased trabecular bone 
volume/total bone volume and trabecular mineralization ratio in animals with low PTH, 
but not in the ones with high PTH. The study reported efficacy in improving bone 
properties when PTH levels are low with anti-sclerostin antibody treatment, however, this 
is the first study using an animal CKD model and, therefore, this results, although 
optimistic, need to be confirmed by other studies. 
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Discussion 
 
CKD is a global health problem with repercussions in the mineral homeostasis that are 
not only responsible for bone lesions, but also for systemic alterations, such as vascular 
calcification. The pathways that lead to these alterations are not restricted to changes in 
calcium and phosphate serum and tissue concentrations and circulating hormones, as 
confirmed by the recent finding of the inhibitory effect of sclerostin in bone formation and 
osteoblast activity.  
ABD prevalence is rising, this time not as a consequence of aluminum overload, but due 
to the generalized usage of calcium-containing phosphate binders and VDR agonists 
that lead to an increase in calcium load and PTH suppression. In ABD patients active 
vitamin D therapy should be avoided and non-calcium phosphate binders should be 
usesdin order to prevent further aggravation of the bone lesion. However, some studies 
have pointed out a benefit in terms of mortality in patients with low PTH when treated 
with VDR agonists. Selective VDR agonists have a lower risk of hypercalcaemia, 
hyperphosphatemia and elevated calcium-phosphate products levels and may present 
as a solution for this new dilemma.  
The association of ABD with peritoneal dialysis, older age, diabetes mellitus and the 
malnutrition-inflammation complex point out the multifactorial etiology of this disease and 
are a reminder of the need to further study ABD to fully understand its mechanisms so 
that we can successfully treat and prevent ABD.  
The gold-standard for the diagnosis of ABD is a bone biopsy with tetracycline labelling. 
However, this is an invasive, expensive and not widely available procedure that, in 
present days, cannot be satisfyingly replaced with biochemical markers. Nonetheless, 
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biochemical abnormalities are the most common indicators by which the diagnosis of 
MBD is made. Extreme values of PTH have a good diagnostic value for ABD and high 
turn-over disease, but in patients with intermediate values the diagnosis is not so clear. 
Newer markers, or combinations of the ones already available should be investigated in 
order to mitigate this diagnostic issue. 
Vascular calcification in a serious consequence of CKD-MBD and it has been associated 
with increased cardiovascular mortality and morbidity. The highest calcification scores 
have also been associated with lower PTH levels, which makes it especially important in 
ABD patients. The true association between sclerostin and vascular calcification has not 
yet been discovered, and more studies need to be conducted in order to fully understand 
it.  
Patients with ABD must have their calcium dialysate reduced in order to prevent 
excessive calcium load. This change translates into a bone histomorphometric 
improvement. As low calcium dialysate may have some hemodynamic consequences, 
an alternative with calcium dialysate profiling is being studied. As calcium-containing 
phosphate binders also contribute to an excessive calcium load, sevelamer and 
lanthanum carbonate are preferred in these patients, with benefic effects on mortality, 
vascular calcification and even bone histomorphometry. 
Novel approaches such as teriparatide, menatetrenone and the anti-sclerostin antibody 
are being proposed as treatment to ABD. However, the studies behind the results 
presented are few and in most cases lack a satisfying number of patients studied as well 
as histomorphometric analysis. Larger studies need to be conducted before definite 
conclusions can be taken on this matter.  
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